Zenobia Therapeutics, founded in 2008 and based in San Diego, specializes in discovering treatments for neurodegenerative diseases through fragment-based lead discovery. In 2014, the company expanded to include Zenobia Fragments, a division that supplies products and services to support fragment-based lead discovery. Their offerings include a diverse fragment library and unique additives for crystallization, catering to both internal CNS research programs and external clients worldwide.

Notable figures associated with Zenobia Therapeutics include its founding team, who are experts in neurodegenerative disease research. The company has attracted significant interest from investors focused on innovative healthcare solutions. Key achievements include the successful identification of hits for a variety of targets using their fragment products. Zenobia's impact is marked by its contributions to advancing treatments for neurodegenerative conditions and supporting global research initiatives through its specialized products and services.